The objective of the present investigation was to prepare bilayer tablets of Glimepride and Metformin HCL in combination 
I. Introduction
Tablets [ 
1, 4]
Pharmaceutical tablets are the dominant dosage forms for drug delivery, occupying two thirds of the global market. Generally, they are formulated by compressing dry powder blends consisting of a number of components with different functionalities in a die.
Multilayered tablets
Layered tablet consists of two or more layers of granulation compressed together. This dosage form has the advantage of separating two incompatible substances. It comprises several different granulations that are compressed to form a single tablet composed of two or more layers and usually each layer is of different colour to produce a distinctive looking tablet. Each layer is fed from distinct feed frame with individual weight control.
Fig 1: Bilayered Tablet
Definition [6] Dual release tablet is a unit compressed tablet dosage form intended for oral application. It contains two parts in which one part having conventional or immediate release part another one is sustained or controlled release part.
Diabetes mellitus
Diabetes mellitus is a metabolic disorder characterized by hyperglycemia, glycosuria, hyperlipemia, negative nitrogen balance and sometimes ketonemia. A wide spread pathological change in thickening of capillary basement membrane, increase in vessel wall matrix and cellular proliferation resulting in vascular complications like lumen narrowing, early atherosclerosis, sclerosis of glomerular capillaries, retinopathy, neuropathy and peripheral vascular insufficiency.
Literature Review
Uttam Mandal et al. designed an oral sustained release sustained matrix tablet of Metformin HCl and optimizes the drug profile using response surface methodology. The tablets were formulated by non aqueous wet granulation method using HPMC K 15M as matrix forming polymer. HPMC K15M and PVP were taken as the independent variables. Asha Patel et al. developed controlled release floating drug delivery system of Metformin HCl microspheres by non-aqueous emulsification solvent evaporation technique using ethylcellulose as the rate controlling polymer and 250 mg of Metformin hydrochloride. The experimental design supported product development and optimization procedure yielded the desired microspheres with drug release equivalent to those of the marketed single unit dosage forms with the added advantage of floatability in gastric juice for prolonged slow release. Cananersoya et al. studied the effect of Metformin on markers of endothelial function, vascular inflammation and factors of thrombosis in obese type 2 diabetic patients. 24 type II diabetic patients (15 female and 9 male) which was previously under medical nutrition treatment (MNT) + regular exercise programme (REP) without chronic micro or macrovascular complications with the mean age of 50.5 ± 1.5 years, diabetes duration of 17.9 ± 6.3 months and body mass index (BMI) of 31.7 ± 0.8 kg/m 2 were enrolled in the study. Subramaniam Kannan et al.performed for the formulation and evaluation of sustained release tablets of Aceclofenac using hydrophilic matrix system to develop once daily sustained release tablets of Aceclofenac (200mg) by wet granulation using hydrophilic polymer like hydroxypropyl methyl cellulose K-100. The drug excipients mixtures were subjected to preformulation studies. The tablets were subjected to physicochemical studies, in-vitrodrug release, kinetic studies and stability studies.
II.
Materials & Methodology 
Drug-Excipient Compatibility Studies by FTIR Spectroscopy
In the present study, the potassium bromide disc (pellet) method was employed. Fourier-transform infrared (FTIR) spectra of the Drug and polymer were obtained on Alpha Brooker FTIR (Tokyo, Japan). The spectra were scanned over the wave number range of 4000 to 400 cm-.
Preparation of matrix tablets
For IR layer (Glimepiride) by direct compression method For SR layer (Metformin HCl) by wet granulation method 
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Evaluation of matrix tablets: Post compression parameters:
The prepared tablets were evaluated for General appearance, thickness, hardness, weight variation, friability and uniformity of weight.
Stability Studies:
The optimized matrix tablets were subjected to stability studies(as per ICH guide lines) at 25°C ± 2°C / 60% ± 5% RH and 40°C ± 2°C / 75% ± 5% RH The products were evaluated for their physical characteristics, drug content, and In-vitro drug release profiles over a period of 3 months.
III. Results

Pre formulation Study Ultraviolet Visible (UV-visible) spectroscopy
Drug sample showed wavelength of maximum absorption (λ-max) 228 nm (Glimepride) and 233nm (Metformin HCl).
Calibration curve of Glimepiride in phosphate buffer pH 1.2 and 6.8 Wavelength of maximum absorption: 228 nm and 233nm respectively. In -vitro drug release study 
Evaluation of Blend
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The dissolution profile of Glimepride IR layer was given in graphical representation, the formulation F6 showed maximum drug release, hence F6 was best formula and F6 IR layer was compressed with Metformin SR layers ( Table 5 , Fig 2) . The dissolution profile of Metformin SR layer was given in graphical representation, the formulation F8 was best among the all formulations (Table 6 , Fig 3) . 
% CDR OF GLIMEPIRIDE IR LAYER
% CDR OF METFORMIN SR LAYER
Higuchi kinetics of SR -F8
Dissolution kinetic parameters of Metformin Hcl
According to above R 2 value, best formulation, i.e, F8 formulation follows higuchi's model which shows that drug is released from matrix (Table 11, Fig 6) .
Stability Studies
There was no significant change in physical and chemical properties of the tablets of formulation F8 after 3 Months (Table 13 ). 
IV. Discussion
In the present study an attempt has been to formulate and evaluate sustained release matrix tablets of Metformin HCl and Glimepride IR layer, employing swellable polymers like Hydroxy propyl methylcellulose(HPMC K100M), Xanthan gum and synthetic polymer Ethylcellulose N-50, Eudragit RS100 were taken along with pharmaceutically acceptable easily available inert excipients and nine formulations were prepared. The formulation was subjected to both pre and post formulation studies. The procured drug sample of Glimepiride and Metformin HCl was tested for its identification by means of organoleptic properties, melting point, UV spectra and FTIR spectrum.
UV Spectroscopic Analytical Method
Standard curve of Glimepiride and Metformin HCl were taken in pH 1.2, wavelengths of maximum absorption was found to be 228 nm and 233nm respectively. The Glimepiride obeyed the Lambert-Beer's law in concentration range of 1-10μg/ml and Metformin obeyed the Lambert-Beer's law at this wavelength. This is well correlated with the reported value (228nm and 233nm).
Drug Interaction Study
FTIR spectra of Metformin HCl and physical mixture of Metformin HCL and polymers (HPMC K100ME and EC) were taken. All the characteristic peaks of pure drug were observed in the spectrum of mixture. This indicated that there was not any interaction between drug and polymer. The granules prepared by wet granulation method were evaluated for various flow properties for SR layer of Metformin HCl.
Physical characterization of Bilayer Tablets of Glimepiride and Metformin HCl
Tablet thickness, hardness, weight variation, friability and drug content of formulated tablets of batches from F1 to F9 for IR layer and F1 to F8 for SR layer are presented in Table 4 .
Uniformity of weight
All the prepared Bilayer tablets of Glimepiride and Metformin HCl were evaluated for weight variation. The weight of all the tablets was found to be uniform with low values of standard deviation and within the prescribed IP limits of ±7.5% (Table 4) .
Hardness and friability
The hardness of the tablet formulations was found to be in the range of 6.3 to 7.2 kg/cm 2 . The friability values were found to be in the range of 0.65to 0.72 % ( Table 4) .
Uniformity of drug content
Percent drug content of all the tablets was found to be in the range of 97.16 to 102.6 percent (which was within the acceptable limits of ±5%) ( Table 4 ).
In vitro dissolution study
In vitro dissolution studies were performed for IR, SR layers, the results are shown in Table 5 , 6. In the dissolution studies the HPMCK100M, Xanthan gum and Ethylcellulose and Eudragit polymers were showing better drug release up to 12hrs.
Model-Dependent Approaches Release Kinetics
To know the drug release kinetics from these formulations, the dissolution data were subjected to different kinetic model such as Zero order and Higuchi's square root kinetics model. The line of equations and regression coefficient of kinetic study for all the formulations are shown in Table 7 , 8, 9, 10, 11 and 12. The regression coefficient was considered as main parameter to interpret release kinetics.
Stability Studies
There was no significant change in physical and chemical properties of the tablets of formulation F6(Glimepiride) and F8(Metformin Hcl) after 3 Months, parameters like % drug release and assay values at various conditions (at 40 0 C/ 75% RH) as per ICH guidelines quantified at various time intervals were shown in Table 13 .
V. Conclusion
This system provides zero order or near zero order release for IR layer and SR layer provides Higuchi model. This concept also demonstrates a wide technology for various applications such as instant release/slow release from one dosage form, because it allows the precise modulation of drug release process even for drug characteristics by extreme physicochemical properties.
